Biohaven Pharmaceutical Sells Participation Rights to Royalty Pharma for $100 Million

June 19, 2018

S&C represents Biohaven Pharmaceutical Holding Company Ltd. in its sale of tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million. Royalty Pharma has also agreed to purchase $50.0 million in common shares of Biohaven. The S&C team on the transaction was led by Krishna Veeraraghavan, Nader Mousavi, Robert Risoleo and Scott Crofton.